Incyte Corp (INCY)
51.63
-0.29
(-0.56%)
USD |
NASDAQ |
Apr 23, 16:00
52.20
+0.57
(+1.10%)
After-Hours: 20:00
Incyte Research and Development Expense (Quarterly): 444.49M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 444.49M |
| September 30, 2023 | 375.71M |
| June 30, 2023 | 400.75M |
| March 31, 2023 | 406.64M |
| December 31, 2022 | 501.36M |
| September 30, 2022 | 384.01M |
| June 30, 2022 | 347.20M |
| March 31, 2022 | 353.37M |
| December 31, 2021 | 472.83M |
| September 30, 2021 | 334.94M |
| June 30, 2021 | 343.51M |
| March 31, 2021 | 306.90M |
| December 31, 2020 | 405.94M |
| September 30, 2020 | 438.11M |
| June 30, 2020 | 286.60M |
| March 31, 2020 | 1.085B |
| December 31, 2019 | 312.87M |
| September 30, 2019 | 281.34M |
| June 30, 2019 | 289.36M |
| March 31, 2019 | 270.54M |
| December 31, 2018 | 304.24M |
| September 30, 2018 | 292.53M |
| June 30, 2018 | 298.09M |
| March 31, 2018 | 303.10M |
| December 31, 2017 | 446.87M |
| Date | Value |
|---|---|
| September 30, 2017 | 269.56M |
| June 30, 2017 | 201.79M |
| March 31, 2017 | 407.92M |
| December 31, 2016 | 161.58M |
| September 30, 2016 | 143.18M |
| June 30, 2016 | 120.27M |
| March 31, 2016 | 156.82M |
| December 31, 2015 | 116.63M |
| September 30, 2015 | 132.07M |
| June 30, 2015 | 112.44M |
| March 31, 2015 | 118.36M |
| December 31, 2014 | 98.72M |
| September 30, 2014 | 88.54M |
| June 30, 2014 | 84.68M |
| March 31, 2014 | 75.58M |
| December 31, 2013 | 75.02M |
| September 30, 2013 | 71.70M |
| June 30, 2013 | 60.95M |
| March 31, 2013 | 52.76M |
| December 31, 2012 | 59.76M |
| September 30, 2012 | 50.08M |
| June 30, 2012 | 51.59M |
| March 31, 2012 | 48.96M |
| December 31, 2011 | 51.88M |
| September 30, 2011 | 44.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
281.34M
Minimum
Sep 2019
1.085B
Maximum
Mar 2020
409.01M
Average
375.71M
Median
Sep 2023
Research and Development Expense (Quarterly) Benchmarks
| Novartis AG | 2.567B |
| MorphoSys AG | 86.49M |
| Illumina Inc | 341.00M |
| Biogen Inc | 570.90M |
| Pfizer Inc | 2.815B |